The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7. The present invention further provides methods of inhibiting AKR1C3 expression or activity, and methods of killing cells that express AKR1C3.Cette invention concerne de nouvelles compositions et méthodes destinées à traiter le cancer de la prostate, p. ex.., un cancer de la prostate résistant aux médicaments, tel quun cancer de la prostate résistant aux anti-androgènes (p. ex., à lenzalutamide) et/ou résistant à la castration(CRPC). Ces nouvelles compositions comprennent, entre autres, des compositions pharmaceutiques qui contiennent un inhibiteur dAR-V7, tel quun niclosamide. En variante, ces nouvelles compositions peuvent comprendre, entre autres, des compositions pharmaceutiques qui contiennent un inhibiteur dAKR1C3, tel quune indométhacine. Les nouvelles méthodes comprennent, entre autres, des méthodes destinées à administrer un inhibiteur dAR-V7, tel quun niclosamide, et/ou un inhibiteur dAKR1C3, tel quune indométhacine, pour traiter des patients ayant un cancer de la prostate. La présente invention concerne également des méthodes destinées à inhiber lexpression dun variant du ré
